Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Apnimed, Inc. (APMD : NSDQ)

• Company Description    Apnimed Inc. is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies which address the neurobiology of sleep-related breathing diseases. Apnimed Inc. is based in CAMBRIDGE, Mass. Number of Employees: 65

• Price / Volume Information    Yesterday's Closing Price: $18.90 Daily Weekly Monthly 20 Day Moving Average: 431,691 shares Shares Outstanding: 41.63 (millions) Market Capitalization: $786.82 (millions) Beta: 52 Week High: $35.29 52 Week Low: $16.12 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -15.96% -16.52% 12 Week % % Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 39 JOHN F. KENNEDY STREET 4TH FLR. - CAMBRIDGE,MA 02138 USA ph: 617-500-8880 fax: - ir@apnimed.com https://apnimed.com

• General Corporate Information    Officers Kevin R. Lind - Chief Executive Officer Paul Sekhri - Chairman Larry Miller - Vice Chairman Dennis Molnar - President and Chief Operating Officer Michael Kelly - Chief Financial Officer Peer Information Apnimed, Inc. (GSAC) Apnimed, Inc. (CASIF) Apnimed, Inc. (ALCD.) Apnimed, Inc. (OMNN) Apnimed, Inc. (CGPI.) Apnimed, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 03770Y107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 12/08/26 Share - Related Items Shares Outstanding: 41.63 Most Recent Split Date: (:1) Beta: Market Capitalization: $786.82 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.24 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 12/08/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -75.94% Sales Growth vs. Year Ago Period: -29.40% vs. Previous Quarter: -85.76% ROE 09/30/26 - - 06/30/26 - - 03/31/26 - - ROA 09/30/26 - - 06/30/26 - - 03/31/26 - - Current Ratio 09/30/26 - - 06/30/26 - 5.19 03/31/26 - 1.91 Quick Ratio 09/30/26 - - 06/30/26 - 5.19 03/31/26 - 1.91 Operating Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Net Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Pre-Tax Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Book Value 09/30/26 - - 06/30/26 - -36.69 03/31/26 - -10.93 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Capital 09/30/26 - - 06/30/26 - - 03/31/26 - -

Powered by Zacks Investment Research ©